Advanced Antibody Explorers
“We bring
science to life.”
AAX Biotech is committed to advancing next-generation therapies for a range of diseases. With a focus on antibody-based medicines, our proprietary technologies aim to solve key challenges in drug development. Our vision is to establish AAX as a leading, highly competitive partner serving the bio-pharma industry worldwide.
About us
We are a research-driven company focused on enabling and accelerating the development of highly effective antibody-based medicines. By offering innovative solutions to well-recognized challenges in the rapidly expanding biotherapeutics market, we aim to accelerate drug development and improve therapeutic outcomes.
News
.
News .
-
AAX Biotech is attending Nordic Health Summit Japan 2024
April 22, 2024
AAX Biotech will be attending the Nordic Health Summit Japan 2024 (virtually), taking place on April 25, 2024 in Tokyo Japan!
At this partnering conference, we look forward to meeting with Japanese pharma companies to discuss AAX Biotech technologies Seqitope™ and Opti-mAb™ to accelerate drug development and enable the development of next-generation antibody therapeutics that are more efficient and with higher developability.
Please feel free to reach out to our CEO Maria Lisa Knudsen to schedule a meeting.
-
AAX Biotech's Technology to be Utilized in BioArctic’s Research Project
April 17, 2024
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is excited to announce that BioArctic AB, a renowned Swedish biopharma company focused on neurodegenerative diseases, has decided to utilize AAX Biotech's proprietary epitope mapping technology, Seqitope™.
This marks a significant milestone for AAX Biotech, highlighting the company's role in advancing research with its Seqitope™ technology—a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
-
AAX Biotech Awarded AbbVie Scandinavia Golden Ticket
April 11, 2024
AAX Biotech is happy to announce its selection as the winner of the AbbVie Scandinavia Golden Ticket. This award grants AAX Biotech access to the SmiLe Incubator's collection of resources, including laboratory and office space, as well as mentoring and business development support, enhancing its efforts in developing antibody-based therapeutics.
As part of the Golden Ticket program, AAX Biotech will gain one year of access to laboratory space, research and office facilities, and services provided by SmiLe Incubator in Lund. Additionally, the company will benefit from mentorship and business coaching from SmiLe, tailored support from AbbVie's international researchers and mentors, and exclusive networking opportunities, paving the way for future collaborations.
